Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.
This page provides a historical news archive for Mural Oncology plc (formerly Nasdaq: MURA), a biotechnology company described in its public communications as a clinical-stage immuno-oncology company. The company focused on using a protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer and maintained its registered office in Dublin, Ireland, with primary facilities in Waltham, Massachusetts.
The news flow around Mural Oncology includes several key themes documented in its press releases. One major strand is the clinical development and subsequent discontinuation of its lead product candidate, nemvaleukin alfa. Announcements in March and April 2025 reported that the Phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer did not meet its primary endpoint and that, after reviewing additional data from the Phase 2 ARTISTRY-6 trial in melanoma, the company decided to discontinue all clinical development of nemvaleukin and terminate other research and development activities, including IL-18 and IL-12 programs.
Another central theme in Mural Oncology’s news record is its exploration of strategic alternatives and eventual acquisition. On April 15, 2025, the company announced that it would explore strategic alternatives focused on maximizing shareholder value, and later updates described cost-conservation measures, including a workforce reduction of approximately 90%. On August 20, 2025, Mural Oncology and XOMA Royalty Corporation announced a definitive transaction agreement under which XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, would acquire the entire issued and to be issued share capital of Mural via an Irish High Court sanctioned scheme of arrangement.
Subsequent news items document shareholder approvals at meetings held on October 24, 2025, the sanction of the scheme by the High Court of Ireland, and the effective date of the acquisition on December 5, 2025. The company also announced that admission of Mural shares to trading on the Nasdaq Global Market was cancelled with effect from the evening of December 4, 2025. Together, these releases provide a detailed timeline of Mural Oncology’s transition from an independent Nasdaq-listed biotech to a wholly owned subsidiary of XOMA Royalty Corporation.
Mural Oncology, a clinical-stage immuno-oncology company, announced on July 1, 2024, the granting of non-statutory stock options and restricted stock units under its 2024 Inducement Stock Option and Incentive Plan. The grants were made as inducements for four newly hired employees under Nasdaq Listing Rule 5635(c)(4). The stock options cover 15,470 ordinary shares at an exercise price of $3.11, with a ten-year term and a vesting schedule of four years. The restricted stock units cover 8,330 ordinary shares, also vesting over four years. Both grants are subject to the terms of respective award agreements and the company's 2024 Inducement Plan.
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced that CEO Caroline Loew, Ph.D., will present at the 14th Annual East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST.
The company focuses on developing engineered cytokine therapies to address unmet needs in cancer treatment. A webcast of the presentation will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.
Mural will also host one-on-one investor meetings during the conference.
Mural Oncology, a clinical-stage immuno-oncology company listed on Nasdaq under the ticker MURA, announced the granting of inducement stock options and restricted stock units to two new employees.
On June 3, 2024, the company awarded non-statutory stock options to purchase 7,995 ordinary shares and restricted stock units for 4,305 ordinary shares under the company's 2024 Inducement Stock Option and Incentive Plan. The options have an exercise price of $3.41 per share, matching the closing price on June 3, 2024, a ten-year term, and vest over four years with 25% vesting after the first year and 6.25% vesting quarterly thereafter. The restricted stock units vest at 25% annually over four years.
These grants were made as an inducement for the employees' new roles, complying with Nasdaq Listing Rule 5635(c)(4).
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.
Preliminary data from ARTISTRY-6 cohorts are expected in 2025.
Mural Oncology (Nasdaq: MURA) announced Q1 2024 financial results and a business update. Key highlights include ongoing clinical trials for nemvaleukin alfa in ovarian cancer and melanoma, with readouts expected in 1H 2025. Mural is also evaluating a new, less frequent IV dose of nemvaleukin. Preclinical data on IL-18 and IL-12 therapies were presented in April 2024, with candidate nominations anticipated by year-end.
Financially, Mural reported a net loss of $30.9 million, improved from $46.5 million YoY. Cash reserves stand at $231.7 million, expected to fund operations into Q4 2025. R&D expenses decreased to $26.9 million, while G&A expenses rose to $7.2 million, reflecting standalone public company costs.
Mural Oncology plc announced the granting of non-statutory stock options and restricted stock units to three newly hired employees as inducement material. The stock options have an exercise price of $3.78 per share, with a ten-year term and vesting over four years. The restricted stock units also vest over four years, 25% per year, subject to continued service with the Company.
FAQ
What is the current stock price of Mural Oncology PLC (MURA)?
What is the market cap of Mural Oncology PLC (MURA)?
